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The host immune system plays a pivotal role in the emergence of tumor cells that are
refractory to multiple clinical interventions including immunotherapy, chemotherapy, and
radiotherapy. Here, we examined the molecular mechanisms by which the immune system
triggers cross-resistance to these interventions. By examining the biological changes in
murine and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection
via cognate cytotoxic T lymphocytes, we found that multimodality resistance arises through
a core metabolic reprogramming pathway instigated by epigenetic loss of the ATP synthase
subunit ATP5H, which leads to ROS accumulation and HIF-1a stabilization under
normoxia. Furthermore, this pathway confers to tumor cells a stem-like and invasive
phenotype. In vivo delivery of antioxidants reverses these phenotypic changes and
resensitizes tumor cells to therapy. ATP5H loss in the tumor is strongly linked to failure of
therapy, disease progression, and poor survival in patients with cancer. Collectively, our
results reveal a mechanism underlying immune-driven multimodality resistance to cancer
therapy and demonstrate that rational targeting of mitochondrial metabolic reprogramming in
tumor cells may overcome this resistance. We believe these results hold important
implications for the clinical management of cancer.
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Introduction
The adaptation of tumor cells to immune surveillance as well as 
the emergence of refractory tumor cells after initial therapy are 
responsible for eventual disease relapse, progression, and metas-
tasis. Multiple tumor-intrinsic mechanisms have been proposed 
to cause tumor drug resistance (1, 2), including the overexpres-
sion of antiapoptotic factors (3), the ejection of pharmacologic 
agents from tumor cells via drug transporters (4), the biochem-
ical or structural modification of the drug target (5–8), and the 
adoption of detoxification or bypass routes (9–14). Furthermore, 
a recent study provides evidence that preferential selection and 
subsequent expansion of a subset of stem-like tumor cells with 
an undifferentiated phenotype contribute to resistance (15). 
However, the potential link between host immune-intrinsic 
mechanisms (i.e., cancer immune editing) and the development 
of resistance to therapy is not well understood. We hypothesized 
that selection pressures imposed by host immune surveillance 
may contribute to drug resistance. In this study, we investigated 
this concept and its underlying mechanisms.
To explore this issue, we developed a system to simulate 
the evolution of cancer cells in a live host and to dissect the 
mechanisms responsible for escape from immune defens-
es mounted by CD8+ cytotoxic T lymphocytes (CTLs), the 
predominant arm of the cancer immune surveillance net-
work (16–18). Through this analysis, we report here that loss 
of the D subunit of mitochondrial ATP synthase (ATP5H) 
constitutes an important pathway through which can-
cer evolution occurs in response to immune editing. Mito-
chondrial ATP5H is a critical component of the energy- 
producing apparatus in eukaryotic cells; thus, disruptions in ATP 
synthase expression in cancer cells would be expected to influ-
ence tumor metabolism. In fact, altered metabolism is a funda-
mental feature of cancer and has been shown to contribute to 
chemo- and radiotherapy resistance (19–21). Tumor mitochon-
drial dysfunction promotes the development of chemoresis-
tance and has increasingly been recognized as an integral target 
for new cancer therapy approaches (22, 23). Likewise, downreg-
ulation of ATP synthase components has been documented in 
a majority of carcinomas (24, 25) and has been associated with 
chemotherapy resistance (26). However, the underlying mech-
The host immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical 
interventions including immunotherapy, chemotherapy, and radiotherapy. Here, we examined the molecular mechanisms by 
which the immune system triggers cross-resistance to these interventions. By examining the biological changes in murine 
and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection via cognate cytotoxic T lymphocytes, we 
found that multimodality resistance arises through a core metabolic reprogramming pathway instigated by epigenetic loss of 
the ATP synthase subunit ATP5H, which leads to ROS accumulation and HIF-1α stabilization under normoxia. Furthermore, 
this pathway confers to tumor cells a stem-like and invasive phenotype. In vivo delivery of antioxidants reverses these 
phenotypic changes and resensitizes tumor cells to therapy. ATP5H loss in the tumor is strongly linked to failure of therapy, 
disease progression, and poor survival in patients with cancer. Collectively, our results reveal a mechanism underlying 
immune-driven multimodality resistance to cancer therapy and demonstrate that rational targeting of mitochondrial 
metabolic reprogramming in tumor cells may overcome this resistance. We believe these results hold important implications 
for the clinical management of cancer.
Mitochondrial reprogramming via ATP5H loss 
promotes multimodal cancer therapy resistance
Kwon-Ho Song,1,2,3 Jae-Hoon Kim,4 Young-Ho Lee,1,2,3 Hyun Cheol Bae,5 Hyo-Jung Lee,1,2,3 Seon Rang Woo,1,2,3 Se Jin Oh,1,2,3  
Kyung-Mi Lee,1,2 Cassian Yee,6 Bo Wook Kim,7 Hanbyoul Cho,4 Eun Joo Chung,8 Joon-Yong Chung,9 Stephen M. Hewitt,9  
Tae-Wook Chung,10 Ki-Tae Ha,10 Young-Ki Bae,11 Chih-Ping Mao,12,13,14 Andrew Yang,14 T.C. Wu,14,15,16,17 and Tae Woo Kim1,2,3
1Department of Biochemistry and Molecular Biology, 2Department of Biomedical Science, College of Medicine, and 3Translational Research Institute for Incurable Diseases, Korea University College of 
Medicine, Seoul, South Korea. 4Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 5Department of Orthopedic Surgery, Seoul 
National University Hospital, Seoul, South Korea. 6Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7Department of Obstetrics and Gynecology, 
International St. Mary’s Hospital, Catholic Kwandong University College of Medicine, Incheon, Seoul, South Korea. 8Radiation Oncology Branch and 9Experimental Pathology Laboratory, Laboratory of 
Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. 10Division of Applied Medicine, School of Korean Medicine, Pusan National University, Yangsan, South Korea. 
11Comparative Biomedicine Research Branch, Research Institute, National Cancer Center, Goyang, South Korea. 12MD-PhD Program, 13Immunology Training Program, 14Department of Pathology, 15Department 
of Oncology, 16Department of Obstetrics and Gynecology, and 17Department of Molecular Microbiology and Immunology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Authorship note: KHS, JHK, YHL, and HCB contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: August 9, 2017; Accepted: June 28, 2018.
Reference information: J Clin Invest. 2018;128(9):4098–4114. 
https://doi.org/10.1172/JCI96804.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 0 9 9jci.org   Volume 128   Number 9   September 2018
Results
Immune editing triggers multimodal resistance to chemotherapy and 
radiotherapy. We first asked whether tumor cells acquire multimodal 
resistance to therapy through immune editing. For this, we subjected 
mouse or human tumor cells transformed with HPV oncoproteins 
(TC-1 or CaSki, respectively) to 3 rounds of in vivo or in vitro selec-
tion by cognate CTLs, respectively, as described previously (18, 28). 
At the end of the selection process, the tumor cells (termed P3) were 
refractory to apoptotic death by cognate CTLs, whereas the parental 
cells (termed P0), or tumor cells mixed for 3 rounds with noncognate 
T cells, remained sensitive to cognate CTLs (18, 28). We compared 
the susceptibility of P3 versus P0 cells to various classes of chemo-
therapy or radiotherapy. On the basis of the LD50 values, we found 
that P3 cells were 10-fold less sensitive to the pharmacologic agents 
cisplatin or 5-fluorouracil (5-FU) relative to P0 cells (Supplemental 
Figure 1, A and B; supplemental material available online with this 
article; https://doi.org/10.1172/JCI96804DS1). P3 cells were also 
much less sensitive to irradiation-induced apoptosis compared with 
P0 cells (Supplemental Figure 1C). Our results indicate that immune 
editing of tumor cells can provoke multimodal resistance to chemo-
therapy, radiotherapy, as well as immunotherapy.
anisms responsible for linking ATP synthase loss to drug resis-
tance have remained unclear.
In this study, we focused on: (a) the mechanisms by which 
immune editing leads to silencing of ATP5H, and (b) the down-
stream pathways by which ATP5H loss promotes multimodal resis-
tance to therapy. We discovered that immune editing alters the epi-
genetic landscape of tumor cells via histone deacetylase 1 (HDAC1) 
upregulation (27), which turns off ATP5H expression via promot-
er deacetylation. The epigenetic loss of ATP5H facilitates cancer 
immune escape and multimodal resistance to immunotherapy, 
chemotherapy, and radiotherapy. Mechanistically, ATP5H loss–
induced mitochondrial reprogramming leads to the accumulation 
of ROS within tumor cells, which stabilizes HIF-1α under normoxia 
and activates the AKT/ERK signaling pathway. Rational targeting of 
this pathway via antioxidants reverses resistance to therapy. In the 
clinical setting, we used tumor tissue biopsies from cancer patients 
and found a strong correlation between loss of ATP synthase and 
overall survival. Our results demonstrate that epigenetic-mediated 
mitochondrial metabolic reprogramming in the course of immune 
editing promotes cancer immune escape and therapy resistance. 
This pathway provides a target for clinical intervention.
Figure 1. Immune editing triggers epigenetic loss of ATP synthase in tumor cells. (A) ATP5H protein levels in TC-1 or CaSki tumor cells at various 
stages of immune editing were determined by Western blot analysis (numbers below each blot are densitometric values). (B) mRNA levels of Atp5h 
(TC-1 cells) or ATP5H (CaSki cells) in TC-1 or CaSki tumor cells at various stages of immune editing were determined by qRT-PCR. (A and B) N1, N2, and 
N3 were generated through serial selection by irrelevant antigen specific CTLs and were used as negative controls. (C) TC-1 or CaSki P0 and P3 tumor 
cells were treated with DMSO, 5-AzaC (5 μM), or TSA (100 nM). Atp5h (TC-1 cells) or ATP5H (CaSki cells) mRNA levels in these cells were probed by 
qRT-PCR. (D) The histone acetylation status of TC-1 or CaSki P0 and P3 cells was determined by ChIP using anti–histone H3 and H4 antibodies, fol-
lowed by qPCR for the Atp5h or ATP5H promoter locus. (E) TC-1 or CaSki P3 cells were treated with or without TSA, and histone H4 acetylation at the 
Atp5h or ATP5H promoter was determined by ChIP-qPCR. (F–H) TC-1 or CaSki P3 cells were transfected with the indicated siRNAs. (F) Atp5h or ATP5H 
mRNA levels were determined by qPCR. (G) Protein levels of HDAC1 and ATP5H were determined by Western blot analysis (numbers below each blot 
are densitometric values). (H) Relative levels of AcH4 at the Atp5h or ATP5H promoter were assessed by qChIP. All experiments were performed in 
triplicate. *P < 0.05 and **P < 0.01, by 1-way ANOVA (B and C) or 2-tailed Student’s t test (D–F and H). Data represent the mean ± SD.
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that immune editing may induce epigenetic silencing of ATP5H 
via histone deacetylation. To verify this, we performed ChIP, 
pulling down histone H3 and H4 and then probing for associated 
Atp5h or ATP5H promoter sequences. We found that histone H4 
acetylation (AcH4) at the Atp5h and ATP5H promoter regions was 
indeed reduced in P3 cells relative to P0 cells (Figure 1D), imply-
ing immune editing–mediated deacetylation of histone H4. Nota-
bly, histone H4 deacetylation at the Atp5h and ATP5H promoter 
loci in tumor cells after selection was reversed by exposure to TSA 
(Figure 1E). Consistent with the unresponsive effects of 5-AzaC on 
Atp5h expression, we did not detect differences in DNA methyla-
tion between tumor cells before or after immune editing (Supple-
mental Figure 3), which suggests that histone deacetylation is the 
primary mechanism underlying ATP5H epigenetic silencing.
We next investigated the factor mediating histone deacetyla-
tion at the Atp5h and ATP5H loci during immune editing. Recent-
ly, we discovered that upregulation of HDAC1 is important for 
epigenetic reprogramming and acquisition of both stem-like prop-
erties and resistance to CTLs by CaSki P3 cells (27). Consistently, 
we observed HDAC1 upregulation upon in vivo immune editing of 
TC-1 tumor cells (Supplemental Figure 4). We hypothesized that 
Immune editing triggers epigenetic silencing of ATP synthase. To 
elucidate the underlying mechanisms responsible for multimodal 
resistance during selection by immune editing, we performed 2D 
protein electrophoresis and mass spectrometry in lysates derived 
from P0 or P3 cells. From this analysis, we noted that subunit D of 
the ATP synthase complex (ATP5H) was downregulated in P3 cells 
compared with that detected in P0 cells (Supplemental Figure 2A 
and Supplemental Table 1; this was then confirmed by Western 
blot analysis (Supplemental Figure 2B). We observed a gradual 
loss of the ATP5H protein in both murine and human tumor cells 
over the course of immune editing (Figure 1A). This gradual pro-
tein loss was accompanied by decreased Atp5h and ATP5H mRNA 
expression, indicating that ATP5H loss was occurring at the tran-
scriptional level (Figure 1B). We reasoned that epigenetic changes 
in tumor cells in the course of immune editing mediate transcrip-
tional loss of ATP5H. To test this, we treated tumor cells (TC-1 
or CaSki), before (P0) or after (P3) sequential immune editing, 
with the DNA methyltransferase (DNMT) inhibitor 5-azacytidine 
(5-AzaC) or the HDAC inhibitor trichostatin A (TSA). Exposure to 
TSA, but not 5-AzaC, upregulated Atp5h and ATP5H transcription 
in P3 TC-1 and CaSki cells, respectively (Figure 1C). This suggests 
Figure 2. Loss of ATP5H converts tumor cells to resistant, stem-like, and invasive phenotypes. (A–F) TC-1 or CaSki P0 cells were transfected with the 
indicated siRNAs. (A) Levels of the various individual protein components of the ATP synthase complex in these cells were probed by Western blotting 
(numbers below the blots are densitometric values). (B) Cells were harvested at the indicated time points and counted after trypan blue staining to 
exclude dead cells. (C) After 72 hours, spontaneous apoptotic cells were determined by flow cytometric analysis of caspase-3 activation. (D) Cells were 
exposed to tumor-specific CTLs, cisplatin, or radiation, and the frequency of apoptotic cells was determined by flow cytometric analysis of caspase-3 
activation. (E) The degree of stem-like and (F) invasive phenotypes in these cells was determined by sphere-forming or Matrigel migration assay. All exper-
iments were performed in triplicate. *P < 0.05 and **P < 0.01, by 2-way ANOVA (B) or 1-way ANOVA (C–F). Data represent the mean ± SD.
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immune editing facilitates epigenetic silencing of ATP5H via 
HDAC1-mediated histone deacetylation.
ATP5H loss confers a stem-like, invasive phenotype to tumor cells 
as well as multimodal resistance to immunotherapy, chemotherapy, 
and radiotherapy. Previously, we found that immune-edited P3 
HDAC1 might be responsible for transcriptional loss of ATP5H. 
Indeed, knockdown of Hdac1 or HDAC1 with siRNA in P3 cells 
raised mRNA and protein levels of ATP5H, which was accompa-
nied by increased histone H4 acetylation at the Atp5h and ATP5H 
promoters (Figure 1, F–H). Altogether, our data demonstrate that 
Figure 3. Immune editing–induced ATP5H loss triggers mitochondrial metabolic reprogramming. (A) Mitochondrial membrane potential was measured 
with JC-1 staining. TC-1 or CaSki cells without (P0) or with (P3) immune editing were stained with JC-1 and then visualized by laser-scanning confocal 
microscopy. Images are representative of 3 separate experiments. Scale bars: 20 μm. Graph shows the ratio of red to green fluorescence intensity. (B) 
Relative mitochondrial membrane potential in P0 versus P3 cells was quantified in JC-1–stained cells by flow cytometry. (C) ATP concentration in P0 and P3 
cells was measured by luciferase-based ATP assay. (D) Relative OCR in P0 versus P3 cells was measured with an extracellular flux analyzer. (E) P0 and P3 
cells were incubated with 2-NBDG for 20 minutes. Intracellular fluorescence of 2-NBDG was detected by flow cytometry. (F) Intracellular lactate levels in P0 
and P3 cells were measured by lactate colorimetric assay. (G–K) TC-1 or CaSki P0 cells were transfected with the indicated siRNAs. (G) Relative mitochon-
drial membrane potential was determined by JC-1 staining. (H) ATP concentration in these cells was measured by luciferase-based ATP assay. (I) Relative 
OCR was measured with an extracellular flux analyzer. (J) Cells were incubated with 2-NBDG for 20 minutes. The intracellular fluorescence of 2-NBDG was 
detected by flow cytometry. (K) Lactate levels in these cells were measured by lactate colorimetric assay. All experiments were performed in triplicate.  
*P < 0.05 and **P < 0.01, by 2-tailed Student’s t test (A–F) or 1-way ANOVA (G–K). Data represent the mean ± SD.
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tumor cells have more tumorigenic, stem-like, and invasive prop-
erties relative to parental P0 tumor cells (16, 29). To determine 
the effects of ATP5H loss on the phenotype of tumor cells, we 
silenced Atp5h or ATP5H expression in P0 cells using siRNA (Fig-
ure 2A). Compared with siGFP-transfected control cells, siAtp5h or 
siATP5H transfection increased the number of viable P0 cells over 
time and reduced spontaneous apoptosis of transfected P0 cells 
(Figure 2, B and C). Furthermore, siAtp5h or siATP5H transfection 
in P0 tumor cells induced multimodal resistance to immunother-
apy, chemotherapy, and radiotherapy (Figure 2D) and conferred a 
stem-like, invasive phenotype (Figure 2, E and F, and Supplemen-
tal Figure 5). Our data indicate that loss of ATP5H is capable of 
phenocopying P3 by converting the tumor cells to antiapoptotic, 
treatment-resistant, stem-like, and invasive phenotypes.
ATP5H loss following immune editing triggers mitochondrial 
metabolic reprogramming. Because ATP5H is an integral part of 
the ATP synthase apparatus, we postulated that immune edit-
ing would also cause mitochondrial dysfunction and metabolic 
reprogramming. Indeed, relative to P0 cells, P3 cells exhibited 
elevated mitochondrial membrane potential (Figure 3, A and 
B), defective ATP production (Figure 3C), reduced oxygen con-
sumption (Figure 3D), enhanced glucose uptake (Figure 3E), and 
increased lactate production (Figure 3F). Knockdown of Atp5h or 
ATP5H in P0 cells with siRNA phenocopied these events (Figure 
3, G–K). Interestingly, there was no alteration in AMPK signaling 
or induction of spontaneous autophagy in P3 cells or siAtp5h- or 
siATP5H-transfected P0 cells compared with control and siGFP- 
transfected P0 cells, suggesting that loss of ATP5H does not exert 
significant metabolic stress on tumor cells (Supplemental Figure 
6). Therefore, we conclude that ATP synthase, and in particular 
the ATP5H subunit, is downregulated as tumor cells undergo 
immune editing. In turn, this loss of ATP synthase triggers mito-
chondrial metabolic reprogramming.
ATP5H loss–induced ROS accumulation mediates resistance to 
cancer therapy. It has been documented that increased mitochon-
drial membrane potential leads to ROS production (30, 31). In 
addition, mitochondrial dysfunction–induced production of ROS 
was reported to affect the chemoresistance phenotypes and malig-
nant behavior of cancer cells (32). In this regard, we observed high 
levels of ROS in P3 cells compared with levels in P0 cells (Figure 
4A), and ROS levels increased gradually with sequential rounds of 
immune editing from P0 to P3 cells (Figure 4B). To directly link 
ROS accumulation to phenotypes of P3 tumor cells, we exposed 
the P3 tumor cells to various therapeutic methods, with or without 
supplementation of antioxidants (N-acetyl cysteine [NAC]) or a 
mitochondria-specific ROS scavenger (MitoTempo). The presence 
of NAC or MitoTempo drastically reduced ROS levels in P3 cells 
(Figure 4C) and restored the susceptibility of P3 cells to immuno-
therapy, chemotherapy, and radiotherapy (Figure 4D), suggesting 
a crucial role of ROS in multimodal resistance of immune-edited 
cancer cells. We hypothesized that the refractory phenotype of 
tumor cells with deficient ATP5H was due to ROS accumulation 
elicited by mitochondrial dysfunction. Notably, knockdown of 
Atp5h or ATP5H in P0 cells increased ROS levels that could subse-
quently be reversed by NAC or MitoTempo supplementation (Fig-
ure 4E). Likewise, NAC or MitoTempo treatment increased the 
sensitivity of siAtp5h- and siATP5H-transfected P0 cells to immu-
notherapy, chemotherapy, and radiotherapy (Figure 4F). Of note, 
we observed no elevation of endogenous antioxidant enzymes 
in P3 cells or siATP5H-transfected P0 cells compared with con-
trol P0 cells (Supplemental Figure 7, A and B). Furthermore, the 
increased ROS levels in P3 cells and siAtp5h- and siATP5H-trans-
fected P0 cells compared with control P0 cells did not increase 
the amount of DNA damage observed in the cells (Supplemental 
Figure 7, C and D). This further suggests that the ROS induced by 
ATP5H loss does not cause significant oxidative toxicity to TC-1 or 
CaSki tumor cells.
Since we observed that knocking down ATP5H in P0 cells 
phenocopied various properties of the P3 cells, we reasoned that 
restoring ATP5H expression in P3 cells could similarly reverse 
the properties of P3 cells to resemble those of P0 cells. Indeed, 
transfection of CaSki P3 cells with ATP5H (Figure 5A) reduced 
the mitochondrial membrane potential (Figure 5B), increased 
ATP production and oxygen consumption (Figure 5, C and D), and 
reduced glucose uptake and lactate production (Figure 5, E and F). 
Furthermore, restoration of ATP5H expression in P3 cells reduced 
ROS levels (Figure 5G) and resensitized P3 cells to immunothera-
py, chemotherapy, and radiotherapy (Figure 5, H–J). Given these 
data, we conclude that ATP5H loss–induced ROS accumulation 
mediates broad-spectrum cross-resistance to cancer therapy.
Delivery of antioxidants overcomes immune and drug resistance 
in vivo. Given our observations in vitro, we reasoned that in vivo 
infusion of antioxidants should reverse multimodal resistance to 
therapy. To test this, we treated TC-1 P3–bearing C57BL/6 mice 
with immunotherapy along with s.c. injection of hydrogel-encap-
sulated NAC (Figure 6A). While immunotherapy alone had no 
effect on tumor growth, dual therapy with E7-specific CTLs and 
NAC retarded tumor growth (Figure 6, B and C) and prolonged 
survival of the mice (Figure 6D). Likewise, in CaSki P3–bearing 
NOD/SCID mice (Figure 6E), while cisplatin monotherapy was 
Figure 4. ATP5H loss–induced ROS accumulation converts tumor cells 
to resistant phenotypes after immune editing. (A) P0 or P3 TC-1 or CaSki 
cells were stained for total mitochondria (Mito, green), mitochondrial 
superoxide (MitoSOX, red), and nuclei (DAPI, blue). Cells were visualized 
under a laser-scanning confocal microscope. Graph depicts the experi-
mental quantitation of MitoSOX fluorescence intensity. Scale bars: 40 
μm. (B) The abundance of ROS (O2–, H2O2) in TC-1 or CaSki tumor cells at 
various stages of immune editing was determined by MitoSOX and DCFH-
DA staining, followed by flow cytometric analysis. Data are presented 
as the mean fluorescence intensity (MFI). (C) P0 or P3 cells were treated 
with PBS, NAC, or MitoTempo. The abundance of ROS in these cells was 
determined by MitoSOX staining, followed by flow cytometric analysis. (D) 
TC-1 or CaSki P3 cells were treated with PBS, NAC, or MitoTempo and then 
exposed to tumor-specific CTLs, cisplatin, or γ-irradiation. The percentage 
of apoptotic cells was measured by flow cytometric analysis of caspase-3 
activation. (E) TC-1 or CaSki P0 cells were transfected with the indicated 
siRNAs. Cells were treated with PBS, NAC, or MitoTempo. The abundance 
of ROS in these cells was determined by MitoSOX staining, followed by 
flow cytometric analysis. (F) siAtp5h no. 1–transfected TC-1 or siATP5H 
no. 1–transfected CaSki P0 cells were treated with PBS, NAC, or MitoTem-
po. Cells were exposed to E7-specific CTLs, cisplatin, or γ-irradiation. The 
frequency of apoptotic cells was determined by flow cytometric analysis  
of caspase-3 activation. All experiments were performed in triplicate.  
*P < 0.05 and **P < 0.01, by 2-tailed Student’s t test (A), 1-way ANOVA (B), 
or 2-way ANOVA (C–F). Data represent the mean ± SD.
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futile, cisplatin combined with NAC curbed tumor growth (Figure 
6, F and G) and prolonged survival (Figure 6H). Thus, we conclude 
that delivery of antioxidants can overcome multimodality resis-
tance of immune-edited tumor cells to therapy.
Loss of ATP synthase activates the HIF-1 pathway through 
ROS-mediated normoxic HIF-1α stabilization. We next examined 
the molecular pathways downstream of mitochondrial metabolic 
reprogramming and ROS accumulation that promote multimodal 
resistance to therapy as a result of ATP5H loss. In this regard, we 
have previously shown that normoxic HIF-1α is markedly upreg-
ulated in tumor cells following selection by immune editing (28). 
While we have established that HIF-1α drives multimodality resis-
tance (Supplemental Figure 8), it is unclear how HIF-1α protein 
expression is induced in immune-edited tumor cells under nor-
moxic conditions. Notably, HIF-1α protein levels before and after 
immune editing are regulated primarily at the translational level 
rather than the transcriptional level, as evidenced by identical 
mRNA levels in P0 and P3 cells (Figure 7A). Under normal oxygen 
tension, HIF-1α becomes hydroxylated and is subsequently target-
ed for degradation by the E3 ubiquitin ligase Von Hippel–Lindau 
(VHL) (33–35). We therefore measured hydroxylated HIF-1α and 
VHL protein levels in P0 versus P3 cells. While P0 and P3 cells had 
similar levels of VHL, the level of hydroxylated HIF-1α was much 
lower in P3 cells than in P0 cells (Figure 7B). The presence of ROS 
has been shown to inhibit conversion of HIF-1α to the hydroxylated 
state (36, 37). Indeed, infusion of antioxidants produced hydroxyl-
ated HIF-1α and markedly reduced HIF-1α levels (Figure 7C). This 
was accompanied by a loss of signaling of other oncogenic com-
ponents, AKT/ERK and VEGF (Figure 7, C and D). Antioxidant 
infusion did not further reduce the level of AKT/ERK signaling in 
P3 cells transfected with siHif1a or siHIF1A (Supplemental Figure 
9), suggesting that ROS mediate AKT/ERK signaling through the 
expression of HIF-1, as reported previously (28).
We then investigated the relationship between ATP5H status 
and HIF-1α expression. Compared with control siGFP–transfected 
cells, siAtp5h- and siATP5H-transfected P0 cells had 4- to 10-fold 
overexpression of HIF-1α (Figure 7E). Furthermore, we found that 
siAtp5h- and siATP5H-transfected P0 cells had markedly higher 
levels of AKT/ERK phosphorylation (p-AKT/p-ERK) and VEGF 
secretion (Figure 7, E and F). In line with this observation, resto-
Figure 5. Restoration of ATP5H reverses mitochondrial metabolism and resistant phenotypes of P3 tumor cells. (A–F) CaSki P3 cells were transfected 
with empty vector (No insert) or ATP5H-FLAG. (A) Levels of endogenous (lower band) and exogenous ATP5H protein (upper band) in these cells were 
analyzed by immunoblotting. Numbers below the blots indicate the fold value for endogenous protein levels of P3 no-insert cells. (B) Relative mitochon-
drial membrane potential in P3 no-insert versus P3 ATP5H cells was quantified in JC-1–stained cells by flow cytometric analysis. (C) ATP concentration in 
P3 no-insert and P3 ATP5H cells was measured by luciferase-based ATP assay. (D) Relative OCR in P3 no-insert versus P3 ATP5H cells was measured with 
an extracellular flux analyzer. (E) P3 no-insert and P3 ATP5H cells were incubated with 2-NBDG for 20 minutes, followed by intracellular fluorescence of 
2-NBDG detection by flow cytometric analysis. (F) Intracellular lactate levels in P3 no-insert and P3 ATP5H cells were measured by lactate colorimetric 
assay. (G) P3 no-insert and P3 ATP5H cells were treated with PBS, NAC, or MitoTempo. The abundance of ROS in these cells was determined by Mito-
SOX staining, followed by flow cytometric analysis. (H–J) P3 no-insert and P3 ATP5H cells were treated with PBS, NAC, or MitoTempo, and then cells 
were exposed to tumor-specific CTLs (H), cisplatin (I), or γ-irradiation (J). The percentage of apoptotic cells was measured by flow cytometric analysis of 
caspase-3 activation. All experiments were performed in triplicate. *P < 0.05 and **P < 0.01, by 2-tailed Student’s t test (B–F), 1-way ANOVA (G), or 2-way 
ANOVA (H–J). Data represent the mean ± SD.
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AKT/ERK signaling pathway (Figure 8, A and B, and Supplemen-
tal Figure 11A). Notably, after drug selection, the tumor cells also 
acquired multimodal resistance to immunotherapy, chemothera-
py, and radiotherapy (Figure 8C) and exhibited stem-like and inva-
sive features (Figure 8D and Supplemental Figure 11A). Infusion 
of antioxidants decreased HIF-1α signaling, reversed cross-resis-
tance, and diminished the sphere-forming and invasive capacity 
of tumor cells (Figure 8, E–G and Supplemental Figure 11B). We 
treated NOD/SCID mice bearing refractory tumor cells with dif-
ferent combinations of cisplatin and hydrogel-encapsulated NAC 
(Figure 8H). We observed that HIF-1α levels were decreased by 
90% in the tumor microenvironment of NAC-treated mice (Sup-
plemental Figure 11C). While cisplatin alone had no effect on 
tumor growth, NAC delivery and cotreatment with cisplatin and 
NAC retarded tumor growth (Figure 8, I and J) and prolonged sur-
vival of the mice (Figure 8K). Thus, we conclude that, as is the case 
with immune editing, drug selection can incite multimodal resis-
tance to therapy. Crucially, we found that this cross-resistance is 
due to mitochondrial metabolic reprogramming mediated by ATP 
synthase loss and can be reversed by the delivery of antioxidants.
The ATP5H/normoxic HIF-1α metabolic reprogramming path-
way is widely conserved in human cancer. To evaluate the role of the 
ATP5H/HIF-1α axis in human cancer, we examined the expression 
of ATP5H and HIF-1α proteins in a large panel of human tumor 
cells, including those derived from patients with cervical, colon, 
liver, breast, prostate, lung, ovarian, or skin cancer. In all of these 
cells, we observed an inverse relationship between ATP5H and 
ration of ATP5H expression in P3 cells markedly reduced the level 
of HIF-1α as well as p-AKT and p-ERK (Supplemental Figure 10). 
Therefore, ATP5H loss, ROS gain, and HIF-1α activation act in a 
linear pathway to govern the resistance of cancer cells to multiple 
classes of therapy.
We next explored the influence of HIF-1α downstream of 
Atp5h or ATP5H silencing on the development of multimodal resis-
tance to therapy after immune editing. Hif1a or HIF1A knockdown 
reversed the AKT/ERK activation and VEGF secretion induced by 
Atp5h or ATP5H knockdown (Figure 7, G and H), indicating that 
the effect of ATP5H loss on resistance is dependent on normoxic 
HIF-1α. Indeed, Hif1a or HIF1A knockdown restored the suscep-
tibility of Atp5h- or ATP5H-depleted tumor cells to immunother-
apy, chemotherapy, and radiation (Figure 7I) and diminished the 
sphere-forming and invasive capacity of these tumor cells (Figure 
7, J and K). Thus, we conclude that the normoxic HIF-1α activation 
is a key control point of multimodal resistance to cancer therapy 
induced by the loss of ATP5H.
Loss of ATP synthase facilitates multimodal resistance following 
drug selection. We next investigated whether, as with immune edit-
ing, drug selection would also prompt loss of ATP synthase. To do 
this, we established cisplatin-refractory tumor cells, termed CaSki 
CR and H1299 CR, by in vivo or in vitro drug selection, respective-
ly. We also used A2780 CP20 tumor cells, a cisplatin-refractory 
variant of A2780 human ovarian cancer cells. We found that after 
drug selection, cisplatin-refractory tumor cells downregulated 
ATP5H, upregulated ROS and normoxic HIF-1α, and activated the 
Figure 6. Delivery of antioxidants reverses resistance-to-therapy phenotype after immune editing. (A) C57BL/6 mice were inoculated with refractory 
TC-1 cells (P3). Mice were administered antioxidants (0.1 mg/kg NAC) via chitosan hydrogel, together with adoptive transfer of E7-specific CTLs at the 
indicated time points. (B) Tumor size was measured every 3 days. (C) The average tumor weight in each group was measured 21 days after tumor challenge. 
(D) Kaplan-Meier analysis of survival in each group. (E) NOD/SCID mice were inoculated with refractory CaSki cells (P3). Mice were administered 0.1 mg/
kg NAC via chitosan hydrogel, together with 2 mg/kg cisplatin at the indicated time points. (F) Tumor size was measured every 3 days. (G) The average 
tumor weight in each group was measured 21 days after tumor challenge. (H) Kaplan-Meier analysis of survival in each group. In vitro experiments were 
performed in triplicate. For in vivo experiments, 10 mice from each group were used. *P < 0.05 and **P < 0.01, by 2-way ANOVA (B and F), 1-way ANOVA (C 
and G), or log-rank test (D and H). Data represent the mean ± SD.
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Figure 7. Loss of ATP5H underlies aberrant activation of the HIF-1α/AKT/ERK signaling pathway. (A) mRNA levels of Hif1a (TC-1 cells) or HIF1A (CaSki 
cells) in TC-1 or CaSki cells without (P0) or with (P3) immune editing was probed by qRT-PCR. (B) Hydroxylated HIF-1α protein and VHL expression were 
probed by Western blotting (numbers below the blots are densitometric values). (C) Expression of HIF-1α as well as phosphorylated and total AKT and 
ERK in TC-1 or CaSki P3 cells was determined by Western blotting in the absence or presence of antioxidants (i.e., NAC or ascorbate). Numbers below the 
blots are densitometric values. (D) VEGF levels in supernatant were determined by ELISA in TC-1 or CaSki P3 cells treated with or without antioxidants.  
(E and F) TC-1 or CaSki P0 cells were transfected with the indicated siRNAs. (E) Western blot analysis of HIF-1α as well as p-AKT and p-ERK levels in 
these cells. Numbers below the blots are densitometric values. (F) ELISA of VEGF secretion by these cells. (G–K) siAtp5h- or siATP5H-transfected TC-1 
and CaSki cells were cotransfected with the indicated siRNAs. (G) HIF-1α as well as p-AKT and p-ERK levels in these cells were probed by Western 
blotting (numbers below the blots are densitometric values). (H) VEGF levels in the supernatant of these cells were determined by ELISA. (I) Cells were 
exposed to E7-specific CTLs, cisplatin, or γ-irradiation. The frequency of apoptotic cells was determined by flow cytometric analysis of caspase-3 activa-
tion. The degree of stem-like (J) and invasive (K) phenotypes in these cells was determined by sphere-forming or Matrigel migration assay, respectively. 
All experiments were performed in triplicate under normoxic conditions. *P < 0.05 and **P < 0.01, by 2-tailed Student’s t test (A, H, and F–K) or 1-way 
ANOVA (D). Data represent the mean ± SD.
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and tumor mitochondrial bioenergetics has not been previously 
explored. Furthermore, to our knowledge, we are the first to report 
a role for ATP5H in cancer immune escape.
It is intriguing, and perhaps counterintuitive, that ATP syn-
thase loss would drive therapeutic resistance in cancer. Nonethe-
less, it has been well documented, in the phenomenon of the War-
burg effect, that tumor cells rely chiefly on glycolysis, as opposed to 
mitochondrial oxidative phosphorylation, for ATP synthesis (42). 
In light of this, our results demonstrate that ATP5H loss in tumor 
cells after selection leads to increased glucose uptake and lactate 
production, suggesting that dysfunction of ATP synthesis contrib-
utes to the Warburg effect. We postulate that disruption of glycoly-
sis in tumor cells (e.g., via inhibition of lactate dehydrogenase) may 
also restore susceptibility to therapy in refractory tumor cells.
Although loss of ATP synthase has been previously observed 
in cancer cells refractory to therapy, such as 5-FU–insensitive 
colon cancer cells (26), the underlying mechanisms responsible 
for linking ATP synthase loss to acquisition of resistance are large-
ly unknown. Here, we have elucidated the signaling pathway by 
which resistance emerges downstream of ATP synthase loss. In 
this regard, we have found that expression of HIF-1α is profoundly 
upregulated — under both normoxia and hypoxia — in tumor cells 
subjected to immune editing by tumor-specific CTLs compared 
with those without selection (28). While we have established that 
the HIF-1α/VEGF axis drives immune escape (28), it is unclear 
how HIF-1α protein expression is induced in tumor cells under 
immune editing. Our present study demonstrated that ATP5H 
loss–mediated mitochondrial dysfunction could accumulate 
ROS, which in turn stabilized HIF-1α in normoxic conditions. The 
results indicated the crucial role of ATP5H loss as the origin of the 
gain of HIF-1α in tumor cells.
Importantly, the inverse relationship between HIF-1α and 
ATP5H expression was widely conserved in tumor cells derived 
from multiple types of human cancer cell lines, as well as in 
tumor tissue from patients with cervical cancer. Also, expression 
of ATP5H and HIF-1α within the tumor correlated strongly with 
disease progression and survival in cancer patients. Thus, our 
data indicate that the expression status of ATP5H (either alone or 
in conjunction with HIF-1α) within tumor tissue may serve as an 
excellent prognostic marker. Furthermore, our results support the 
development of rational therapies aimed at restoring ATP synthase 
activity or reducing ROS accumulation. As proof of this principle, 
we demonstrated that treatment with antioxidants could abol-
ish HIF-1α expression in tumor cells following immune editing, 
restore sensitivity to lysis by CTLs, and effectively control tumor 
growth in mice transferred with tumor-specific CTLs. Therefore, 
the clinical administration of antioxidants may overcome the 
problem of acquired resistance to immune-based therapies.
Downregulation of ATP synthase subunits has been reported 
in multiple human carcinomas (24, 25). This raises the obvious 
question of precisely how ATP5H loss occurs in the course of can-
cer evolution. Our data point to epigenetic alteration at the Atp5h 
or ATP5H gene locus as a result of immune editing. In particular, 
we have found that selection prompts histone deacetylation at the 
Atp5h or ATP5H promoter and provokes the transcriptional loss 
of ATP5H in tumor cells. It is important to define the chromatin 
modifier involved in this epigenetic process. Recently, we demon-
HIF-1α expression (Figure 9, A and B). Furthermore, knockdown 
of ATP5H expression in these tumor cells markedly upregulated 
normoxic HIF-1α and ROS (Figure 9, C and D, and Supplemental 
Figure 12). ATP5H knockdown also conferred multimodality resis-
tance to immunotherapy, chemotherapy, and radiotherapy (Fig-
ure 9, E–G), as well as a more pronounced sphere-forming, inva-
sive phenotype (Figure 9, H and I). These results demonstrate that 
the biochemical and functional properties of the ATP5H/HIF-1α 
axis are conserved across multiple types of cancer cells.
Loss of ATP synthase is associated with aggressive disease and poor 
prognosis in cancer patients. To determine the clinical relevance of 
the ATP5H/HIF-1α axis in human cancer, we first performed IHC 
for ATP5H and HIF-1α on tumor tissue sections from patients 
with established cervical carcinoma at various defined stages 
(Supplemental Figure 13). We found that patients with early- 
stage (I–IIA) cancer had high ATP5H and low HIF-1α expression 
levels; by contrast, patients with late-stage (IIB–IV) cancer had 
low ATP5H and high HIF-1α expression levels (Figure 10A). In 
addition, when we stratified patients into groups of those with an 
ATP5Hhi HIF-1αlo versus ATP5Hlo HIF-1αhi tumor phenotype, we 
found, strikingly, that 80% of the patients with early-stage cancer 
had the ATP5Hhi HIF-1αlo phenotype, while 90% of the patients 
with late-stage cancer had the ATP5Hlo HIF-1hi phenotype (P < 
0.001) (Figure 10B), reflecting a clinically compelling correlation 
between activation of the ATP5H/HIF-1α axis and tumor aggres-
siveness. More important, patients with low ATP5H expression in 
the tumor also had a poor prognosis compared with those with 
high ATP5H expression (P < 0.002), and the effect of ATP5H loss 
became even more pronounced when examined in conjunction 
with HIF-1α status (P < 0.001) (Figure 10C). In fact, over 80% of 
patients with the ATP5Hlo HIF-1αhi tumor phenotype had a large 
tumor mass (>4 cm), lymph node metastasis, and poor response 
to chemoradiotherapy, consistent with our data from cell-based 
systems in this study (Table 1 and Supplemental Table 2). On 
the other hand, the majority of patients with the ATP5Hhi HIF-
1αlo tumor phenotype had a small tumor (<4 cm), no lymph node 
metastasis, and a positive response to chemoradiotherapy (Table 
1 and Supplemental Table 2). Remarkably, ATP5H expression in 
the tumor was a stronger predictor of overall survival compared 
with disease stage/grade, tumor size, or presence of lymph node 
metastasis (Table 2). Thus, we conclude that the ATP5H/HIF-1α 
axis is conserved in patients with cancer and serves as a clinical 
determinant of disease prognosis.
Discussion
The adaptation of tumor cells to host immune defenses has 
emerged as a major driving force for cancer onset and progression 
(38). This adaptation may occur through host-intrinsic events, 
such as the induction of tolerance to tumor antigen in tumor- 
specific CTLs, or the recruitment of Tregs or myeloid-derived sup-
pressor cells to the tumor microenvironment (39). Alternatively, 
adaptation may be controlled by tumor-intrinsic events, such as 
loss of antigen or gain of resistance to apoptosis (40, 41). Here, 
we show that tumor adaptation to immune surveillance can be 
triggered by the metabolic state of tumor cells via mitochondri-
al reprogramming through loss of ATP synthase, in particular its 
D subunit (ATP5H). The link between host immune surveillance 
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tumor cells helps facilitate progression and metastasis (45–47). In 
the current study, we observed that elevated ROS levels caused by 
treatment selection–induced ATP synthase dysfunction served as a 
critical process for the generation of multimodal therapy resistance 
and that antioxidant supplementation has the potential to restore 
the sensitivity of tumor cells to various treatments.
Altogether, our data provide evidence that selection pres-
sure within the tumor microenvironment — such as that imposed 
by immunotherapy, chemotherapy, or radiotherapy — provokes 
the loss of ATP5H within a subset of tumor cells. These ATP5H- 
deficient cells consequently undergo metabolic reprogramming 
and acquire a multimodal resistant phenotype. Furthermore, 
rational targeting of metabolic reprogramming within the tumor 
has the potential to overcome multimodal resistance to therapies.
Methods
Cells. The production and maintenance of HPV-16 E7+ TC-1 cells (P0, P1, 
P2, P3) and CaSki cells (P0, P1, P2, P3) have been described previously 
(18, 28). To generate in vivo cisplatin–refractory CaSki cells, NOD/SCID 
mice were inoculated s.c. with CaSki cells. One week after the inocula-
tion, CaSki cell–bearing mice were administered cisplatin (2 mg/kg, i.p.) 
once every three weeks. One of the outgrowth tumors resistant to cispla-
tin was explanted and expanded in vitro. After 2 rounds of in vivo drug 
selection, we obtained CaSki CR cells that were completely resistant to 
cisplatin in vivo. To generate in vitro H1299 CR cells, H1299 cells were 
treated with cisplatin (IC50: 6.7 μM) for 72 hours and then incubated 
for a further 72 hours without cisplatin. This sequential treatment was 
repeated for approximately 6 months. Ultimately, we obtained H1299 
CR that was resistant to cisplatin in vitro. CUMC6, HeLa, CaSki, SiHa, 
DU145, PC-3, HepG2, HCT116, A549, H1299, NCI H1703, HCC95, 
SW620, LOVO, HT29, LNcap, MDA435, A2780, A2780 CP20, SK-OV3, 
OVCAR3, A375, and 526Mel cells were acquired from the Ameri-
can Type Culture Collection (ATCC); SNU-C4, SNU423, MCF-7, and 
MDA231 cells were acquired from the Korean Cell Line Bank (KCLB). 
All cell lines were recently authenticated.
Mice. Six- to eight-week-old female C57BL/6 and NOD/SCID 
mice were purchased from Central Lab Animal Inc.
Chemicals and reagents. NAC and ascorbate (MilliporeSigma) 
were used as ROS scavengers. DCF-DA and MitoSOX Red (Invitro-
gen, Thermo Fisher Scientific) were used for ROS detection in cells. 
MitoTempo (MilliporeSigma) was used as a specific scavenger of mito-
chondrial superoxide. Cisplatin and 5-FU (MilliporeSigma) were used 
as cytotoxic pharmacologic agents. 5-AzaC (MilliporeSigma) and TSA 
(Selleckchem) were used to inhibit DNA methyltransferase and HDAC, 
respectively. An ATP5H plasmid (RC207908, Origene Technologies) 
was used to restore ATP5H expression in treatment-resistant cells.
Antibodies. Primary antibodies against phosphorylated AKT 
(p-AKT) (no. 9271), AKT (no. 9272), p-ERK (no. 9101), ERK (no. 9102), 
HDAC1 (no. 5356), hydroxyl HIF-1α (no. 3434), γ-H2AX (no. 2577), 
p-AMPKα (no. 2535), AMPKα (no. 2532), and LC3B (no. 2775) were 
obtained from Cell Signaling Technology. Primary antibodies against 
VHL (sc-5575, Santa Cruz Biotechnology), TRX (sc-20146, Santa Cruz 
Biotechnology), HIF-1α (NB100-131, Novus Biologics), ATP5C (NBP2-
15525, Novus Biologics), AcH3 (06-599, MilliporeSigma), AcH4 (06-
866, MilliporeSigma), MnSOD (06-984, MilliporeSigma), ATP5H 
(ab110275, Abcam), ATP5A (ab14748, Abcam), ATP5B (ab14730, 
Abcam), ATP5O (ab110276, Abcam), ATP5D (PA5-21361, Ther-
strated the crucial role of HDAC1 in epigenetic silencing events 
of tumor cells during immune editing (27). Indeed, knockdown 
of Hdac1 or HDAC1 in TC-1 and CaSki tumor cells after immune 
editing led to an increase in ATP5H levels (Figure 1, G and H), a 
reduction of ROS, and a decrease in HIF-1α protein expression and 
VEGF secretion by tumor cells (Supplemental Figure 14). There-
fore, our data indicate that HDAC1-mediated histone deacetyl-
ation facilitates epigenetic silencing of ATP5H in the course of 
immune editing and is hence a driver of cancer immune escape 
via mitochondrial reprogramming.
Surprisingly, our data also reveal defective ATP synthesis itself 
as the basis for resistance to therapy. Notably, when we ectopical-
ly silenced the expression of a different ATP synthase component 
(ATP5A) in tumor cells, we also observed a reduction in oxygen 
consumption, an elevation of ROS levels, as well as stabilization 
of HIF-1α (Supplemental Figure 15). These data suggest that loss 
of other ATP synthase components (other than ATP5H) may simi-
larly dampen the ATP synthase machinery and mitochondrial oxi-
dative phosphorylation, leading to the development of multimo-
dality resistance to therapy. Curiously, however, only the ATP5H 
subunit was consistently downregulated after immune selection, 
hinting that expression of the various components of the ATP syn-
thase complex may be regulated in different ways.
It should be noted that the role of ROS in mediating tumor pro-
gression remains a complex and controversial matter. While elevat-
ed ROS levels in cancer cells have been suggested to contribute to 
cancer cell growth, angiogenesis, and metastasis (43), thus prompt-
ing the use of antioxidants as potential anticancer therapy, antiox-
idant supplementation has not been shown to confer a significant 
treatment advantage to cancer patients in various clinical trials 
(for review, see ref. 44). Furthermore, in certain tumor types, it has 
been suggested that upregulation of endogenous antioxidants by 
Figure 8. Chemoselection triggers ATP5H lost, mitochondrial repro-
gramming, and resistance to multimodal therapy. (A) ATP5H and HIF-1α 
levels were probed in drug-sensitive (P) or refractory (CR) human cancer 
cells by Western blotting (numbers below blots are densitometric values). 
Note: CP20 is a refractory version of A2780 cells. (B) ROS levels (O2–) were 
determined by MitoSOX staining, followed by flow cytometric analysis. (C) 
P or CR cells were exposed to granzyme B, cisplatin, or γ-irradiation. The 
frequency of caspase-3–positive apoptotic cells was determined by flow 
cytometric analysis. (D) The degree of stem-like and invasive phenotypes 
of cells was determined by sphere-forming or Matrigel migration assay. 
Scale bars: 100 μm (top) and 20 μm (bottom), respectively. (E–G) CR tumor 
cells were incubated with or without antioxidants (NAC). (E) HIF-1α levels 
were probed by Western blotting (numbers below blots are densitometric 
values). (F) Cells were exposed to granzyme B, cisplatin, or γ-irradiation. 
The frequency of caspase-3–positive apoptotic cells was determined by 
flow cytometric analysis. (G) The degree of stem-like and invasive phe-
notypes in cells was determined by sphere-forming or Matrigel migration 
assay. Scale bars: 100 μm (top) and 20 μm (bottom), respectively. (H) NOD/
SCID mice were inoculated with CaSki-CR cells. Mice were administered 
NAC (0.1 mg/kg) via chitosan hydrogel, together with cisplatin (2 mg/kg), 
at the indicated time points. (I) Tumor size was measured every 3 days. (J) 
The average tumor weight in each group was measured 21 days after tumor 
challenge. (K) Kaplan-Meier analysis of survival in each group. All in vitro 
experiments were performed in triplicate under normoxic conditions. For 
in vivo experiments, 10 mice from each group were used. *P < 0.05, **P < 
0.01, and ***P < 0.001, by 2-tailed Student’s t test (B–D, F, and G), ANOVA 
(I and J), or log-rank test (K). Data represent the mean ± SD.
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5′-UUAUGUUCCUCAUUUUCUCCA-3′ (sense) and 5′-GAGAAAAU-
GAGGAACAUAAUU-3′ (antisense) for mouse siAtp5h (no. 2), 
5′-UAAUAAUUAUACAGUUAAA-3 (sense) and 5′-AUUAUUAAU-
AUGUCAAUUU-3′ (antisense) for human siATP5H (no. 1), and 
5′-GAAGCUCUGGCCCUUGUAU-3′ (sense) and 5′-AUACAAGG-
GCCAGAGCUUC-3′ (antisense) for human siATP5H (no. 2). The 
sequences were 5′-GAGUCAAAACAGAGGAUGA-3′ (sense) and 
5′-UCAUCCUCUGUUUUGACUC-3′ (antisense) for mouse Hdac1 
and 5′-GAGUCAAAACAGAGGAUGA-3′ (sense) and 5′-UCAUCCU-
CUGUUUUGACUC-3′ (antisense) for human HDAC1. The siRNA for 
GFP (5′-GCAUCAAGGUGAACUUCAA-3′ [sense]; 5′-UUGAAGUU-
mo Fisher Scientific), NANOG (A300-397A, Bethyl Laboratories), 
catalase (K90136S, BioDesign International), and β-actin (M177-3, 
MBL International) were acquired and used in this study.
siRNAs. Synthetic siRNAs were synthesized by Bineer (Deajeon, 
Korea). The synthetic siRNA sequences were 5′-CCAGATCTCG-
GCGAAGTAA-3′ (sense) and 5′-UUACUUCGCCGAGAUCUGG-3′ 
(antisense) for mouse Hif1a siRNA and 5′-CCUAUAUCCCAAUG-
GAUGAUG-3′ (sense) and 5′-CAUCAUCCAUUGGGAUAUAGG-3′ 
(antisense) for human HIF1A siRNA. The sequences were 5′-AAUC-
UUCAGGGCAUUAUACUUCU-3′ (sense) and 5′-AGAAGUC-
CCGAUAAUAUGAAGAAA-3′ (antisense) for mouse siAtp5h (no. 1), 
Figure 9. Broad-spectrum cross-resistance to conventional therapeutic agents mediated by ATP5H loss is widely conserved in human cancer. (A) 
Western blot analysis of HIF-1α and ATP synthase subunit D (ATP5H) expression in various types of human tumor cells. (B) Linear regression analysis of 
the relationship between HIF-1α and ATP5H expression in human cancers. Value 1 refers to the expression level of CaSki cells. (C–I) Various types of human 
tumor cells were transfected with siRNAs against GFP or ATP5H. (C) ATP5H and HIF-1α levels were measured by Western blotting (numbers below the 
blots are densitometric values). (D) ROS (O2–) abundance was determined by MitoSOX staining, followed by flow cytometric analysis. Transfected cells were 
exposed to granzyme B (E), cisplatin (F), or γ-irradiation (G). The frequency of apoptotic cells was determined by flow cytometric analysis of caspase-3 
activation. The degree of stem-like (H) and invasive (I) phenotypes in transfected cells was determined by sphere-forming or Matrigel migration assay, 
respectively. All experiments were performed in triplicate under normoxic conditions. *P < 0.05, **P < 0.01, and ***P < 0.001, by 2-tailed Student’s t test. 
Data represent the mean ± SD.
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crosslinking, the immunoprecipitated sample and input were incubated 
at 65°C overnight. After reversal of crosslinking, DNA fragments were 
purified on spin columns (MilliporeSigma). For qChIP assays, DNA 
immunoprecipitated by rabbit IgG, AcH3, or AcH4 was quantified by 
real-time qPCR using following the primer sets: mAtp5h, 5′-GCCTTC-
CAGGACGGGACTCCAT-3′ (forward) and 5′-GTCCGTGGAGAT-
TCGACCCAACAC-3′ (reverse) and hATP5H, 5′-TTGGCTGATCTG-
CGAAGCA-3′ (forward) and 5′-GTAACGGAAGTGGGTCACGG-3′ 
(reverse). Each sample was assayed in triplicate, and the amount of pre-
cipitated DNA was calculated as the percentage of input sample.
ELISA. VEGFA concentration in supernatant of TC-1 P0, P3, 
and CaSki P0 and P3 cells collected at 48 hours was measured with a 
mouse and human VEGFA Quantikine ELISA Kit (R&D Systems). The 
VEGFA concentration was normalized to the number of cells in each 
sample and depicted as picograms VEGFA per 106 cells.
Confocal microscopy. TC-1 P0 and P3 and CaSki P0 and P3 cells 
were seeded at 2 × 104 cells per 2-well culture slide (SPL Life Scienc-
es) in DMEM supplemented with 10% FBS and incubated overnight. 
To detect mitochondrial membrane potential, cells were treated with 
5 μM JC-1 dye (Invitrogen, Thermo Fisher Scientific) for 20 minutes. 
For detection of mitochondrial ROS, seeded cells were transfected 
with CellLight Mitochondria-GFP (Invitrogen, Thermo Fisher Sci-
entific) and incubated overnight. Cells were treated with MitoSOX 
(5 μM) (Invitrogen, Thermo Fisher Scientific) for 30 minutes. TC-1 P0 
and P3 and CaSki P0 and P3 cells were fixed in 4% paraformaldehyde 
for 10 minutes. Cells were washed with PBS, treated with 0.2% Tri-
ton X-100, and blocked for 1 hour in 1% BSA. Nuclei were stained with 
DAPI (Invitrogen, Thermo Fisher Scientific).
CACCUUGAUGC-3′ [antisense]) was used as a nonspecific control. 
Tumor cells (105 cells) were transfected in 6-well plates with 100 
pmol synthesized siRNAs with Lipofectamine 2000 (Invitrogen, 
Thermo Fisher Scientific).
Quantitative reverse transcription PCR. Total RNA was extracted 
with the RNeasy Mini Kit (QIAGEN) and treated with DNase (Ambi-
on, Thermo Fisher Scientific). Quantitative reverse transcription 
PCR (qRT-PCR) mixtures were assembled with 1 μl cDNA template, 
iQ SYBR Green Supermix (Bio-Rad), and primers for Hif1a, HIF1A, 
Atp5h, or ATP5H. PCR was carried out for 40 cycles with the follow-
ing thermal cycling conditions: 95°C for 10 seconds (denaturation) 
and 61°C for 60 seconds (annealing). All data were normalized to 
Actb mRNA expression levels.
Western blot analysis. Lysate extracted from a total of 1 × 105 cells 
was used to perform Western blot analysis, as described previously 
(18). Immunoreactive bands were developed with the Chemilumines-
cence ECL Detection System (Elpis-Biotech), and signals were detect-
ed using the LAS-4000 Mini Luminescent Image Analyzer (Fujifilm).
ChIP and quantitative ChIP assays. The ChIP Kit (MilliporeSigma) 
was used according to the manufacturer’s instructions, and ChIP assays 
were performed as described previously (16). Briefly, cells (107 per 
assay) were bathed in 1% formaldehyde (MilliporeSigma) at 25°C for 10 
minutes for the crosslinking of proteins and DNA and then lysed in SDS 
buffer containing protease inhibitor. DNA was sheared to 0.2- to 1-kb 
fragments by sonication using a Sonic Dismembrator Model 500 (Ther-
mo Fisher Scientific). Immunoprecipitation was performed by incuba-
tion with 1 μg anti-AcH3 and anti-AcH4 (MilliporeSigma) antibodies 
or rabbit IgG (MilliporeSigma) for 16 hours. To reverse protein-DNA 
Figure 10. Expression status of ATP5H in tumor 
tissue influences disease outcome in patients 
with cancer. (A) Representative immunohisto-
chemical analysis of ATP5H  and HIF-1α expres-
sion in tumor tissue from patients with cervical 
cancer. Scale bars: 200 μm. Original magnifica-
tion, ×20 (insets). The experiment was repeated 
at least 3 times. (B) Correlation between ATP5H 
and HIF-1α expression in tumor tissue from 
patients with cervical cancer. (C) Kaplan-Meier 
analysis of disease-free survival among patients 
with cervical cancer, stratified by ATP5H and 
HIF-1α expression status in tumor tissue 
specimens. Expression status was assessed 
by IHC and computed from an algorithm that 
considered both the intensity and total stained 
tissue area. P values were calculated by 2-tailed 
Student’s t test (B) or log-rank test (C).
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peptide (10 μg/ml) for 1 hour and then 
mixed with cognate MART-1 or control 
noncognate NY-ESO1–specific CD8+ 
CTLs at a 1:1 ratio and incubated for 4 
hours at 37°C. Cells were stained for 
active caspase-3 as an index of apopto-
sis and examined by flow cytometry.
Granzyme B–mediated apoptosis 
assay. Recombinant human granzyme B 
(Enzo Life Sciences) was mixed with Bio-
Porter Reagent (MilliporeSigma) at 25°C 
for 5 minutes. Tumor cells were mixed 
with BioPorter–granzyme B complexes 
for 4 hours at 37°C. Cells were stained for 
active caspase-3 as an index of apoptosis 
and examined by flow cytometry.
Cisplatin-mediated apoptosis assay. 
Tumor cells were seeded at 2 × 105 
cells/well in 6-well plates 1 day before 
the assay. Cells were treated with 10 
μM cisplatin for 24 hours and then harvested by trypsinization. The 
frequency of apoptotic cells was determined by staining with anti–
active caspase-3 antibody, followed by flow cytometric analysis.
γ-Irradiation–mediated viability assay. Cells were subjected to irra-
diation with a range of doses (0, 2, 4, 8, or 10 Gy) with a 137Cs radiator 
at a rate of 2.01 Gy/min and seeded onto tissue culture plates. After 
culture for 96 hours, viability was measured by trypan blue exclusion 
assay or active caspase-3 assay. After treatment with NAC, the cells 
were irradiated at 2 Gy.
Tumor sphere–forming assay. Cells were plated at 2 × 103 cells per 
well in 24-well, super-low-adherence vessels (Corning) containing 
serum-free DMEM-F12 (Thermo Fisher Scientific) supplemented 
with EGF (20 ng/ml), basic FGF (20 ng/ml), and 1× B27 supplement. 
Medium was replaced every 3 days to replenish nutrients. Cells were 
examined under a light microscope, and colonies of greater than 2 mm 
in diameter were counted as spheres.
In vitro invasion assay. Twenty-four-well culture inserts were pre-
coated with Matrigel (Corning) Basement Membrane Matrix (BD Bio-
Mitochondria analysis. To detect mitochondrial membrane potential, 
cells were stained with 5 μM JC-1 dye (Invitrogen, Thermo Fisher Scien-
tific) for 20 minutes at 37°C. The fluorescence intensity of JC-1 aggre-
gates was determined by flow cytometry as an index of the mitochondrial 
membrane potential. Flow cytometry was performed on a FACSCalibur 
device with CellQuest Pro software (both from BD Biosciences).
Metabolic analysis. ATP concentration was determined with an 
ATP Bioluminescent Assay Kit (MilliporeSigma). Cell lysate was incu-
bated with ATP Assay Mix Solution containing luciferase and lucifer-
in. Luciferase activity was measured as an index of ATP concentra-
tion with a TD-20/20 Luminometer (Turner Biosystems). The oxygen 
consumption rate (OCR) was measured at 37°C with an XF96 instru-
ment (Seahorse Bioscience). Glucose uptake was analyzed using 
2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose 
(2-NBDG) (Invitrogen). Cells were cultured in glucose-free RPMI 
medium and then incubated with 50 μM 2-NBDG for 1 hour at 37°C. 
2-NBDG–positive cells were measured by flow cytometry. Lactate 
production was measured with a Lactate Assay Kit (Bio Vision). Cell 
culture medium was incubated with a lactate 
assay buffer containing lactate enzyme for 30 
minutes. Lactate levels were measured with 
a uQuant Microplate Reader (BioTek) at 570-
nm wavelength.
Spontaneous apoptosis assay. TC-1 or CaSki 
P0 cells were transfected with siGFP, siAtp5h 
(no. 1), siAtp5h (no. 2), siATP5H (no. 1), or 
siATP5H (no. 2). After 72 hours, the frequen-
cy of spontaneous apoptotic cells was deter-
mined by staining with anti–active caspase-3 
antibody followed by flow cytometric analysis.
CTL-mediated apoptosis assay. TC-1 cells 
or CaSki cells were labeled with CFSE (10 
μM) in DMEM supplemented with 0.1% FBS. 
The CFSE-labeled TC-1 cells were mixed with 
E7-specific CD8+ CTLs at a 1:1 ratio and then 
incubated for 4 hours at 37°C. The CFSE- 
labeled CaSki cells were pulsed with MART1 
Table 2. Univariate and multivariate analyses of overall survival in patients with cervical 
cancer
Variables Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95%CI) P value
Age (>50 yr) 1.04 (0.41–2.59) 0.929 NA
FIGO stage (>IIB) 4.57 (1.81–11.51) 0.001 3.55 (1.20–10.50) 0.022
Cell type (non-SCC) 2.36 (0.89–6.25) 0.082 NA
Grade (poor) 2.27 (0.89–5.77) 0.083 NA
Tumor size (>4 cm) 1.71 (0.66–4.40) 0.263 NA
LN metastasis 2.39 (0.79–7.25) 0.123 NA
SCC Ag+ 3.38 (1.28–8.90) 0.014 2.04 (0.70–5.94) 0.189
ATP5H– A 5.49 (1.59–18.99) 0.007 3.99 (1.06–14.94) 0.040
HIF-1α+ B 4.87 (1.60–14.82) 0.005 3.59 (1.14–11.29) 0.029
ATP5H–/HIF-1α+ 14.40 (1.85–111.66) 0.011 11.67 (1.35–100.72) 0.025
ACutoff value of ATP5H+ is 5 points above the IHC score. BCutoff of HIF-1α+ is 6 points above the IHC 
score. NA, not applicable; SCC, squamous cell carcinoma.
Table 1. Correlation between the expression status of ATP5H and HIF-1α in the 
tumor microenvironment and tumor size, lymph node metastasis, and response to 
chemoradiotherapy in patients with cancer
Advanced tumor 
phenotypes
Expression of combination markerA Correlation  
coefficient (R)
P value
ATP5H–/HIF-1α+ ATP5H+/HIF-1α–
N % N %
Tumor size –0.441 <0.001
  ≤4 cm 18 40.9 26 59.1
  >4 cm 20 87.0 3 13.0
LN metastasis –0.403 0.002
  Negative 17 38.6 27 61.4
  Positive 12 85.7 2 14.3
Chemoradiation response –0.400 0.012
  Good 11 36.7 19 63.3
  Bad 9 81.8 2 18.2
ACutoff value of ATP5H+ and HIF-1α+ is 6 or 8 points above the IHC score, respectively. FIGO, International 
Federation of Gynecology and Obstetrics; LN metastasis, lymph node metastasis; N, number.
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IHC. Paraffin sections were cut to 5-μm thickness, deparaffinized 
with xylene, and rehydrated with graded ethanol. Antigen retrieval 
was performed in a pressure cooker containing citrate buffer at pH 9.0 
(Dako) for ATP5H and pH 6.0 (Dako) for HIF-1α, and sections were 
incubated in 3% H2O2 for 10 minutes. The sections were then incu-
bated with anti-ATP5H antibody (mouse monoclonal, clone 7F9BG1, 
Invitrogen, Thermo Fisher Scientific) at 1:1,000 dilution for 2 hours 
or with anti–HIF-1α antibody (mouse monoclonal, clone ESEE122, 
Novus Biologics) at 1:2,000 dilution for 30 minutes at room tempera-
ture. Samples were then incubated with an EnVision Dual Link (Dako) 
secondary antibody for 30 minutes. Samples were visualized with 
diaminobenzidine (Dako), counterstained with hematoxylin, dehy-
drated in ethanol, and cleared in xylene. Negative controls (substitu-
tion of the primary antibody with TBS) were run simultaneously.
Digital image analysis. IHC tissue sections were converted into dig-
ital format at ×20 magnification with a Scanscope CS device (Aperio) 
and annotated with Digital Image Hub software (SlidePath). Annotat-
ed regions were subjected to image analysis with Tissue IA version 3.0 
software (SlidePath). An algorithm was developed within the Tissue 
IA software program to quantify ATP5H and HIF-1α expression on the 
basis of intensity and stained tissue area. These parameters were com-
bined to assign an IHC score of 0 to 12 to each sample, representing 
minimal to maximal levels of expression, respectively.
Statistics. All data are representative of at least 3 separate exper-
iments. Group differences were analyzed using a 2-tailed Student’s t 
test. Statistical analyses of multiple groups within experiments were 
performed using 1- or 2-way ANOVA. For IHC data, statistical analysis 
was performed using R software, version 3.1.2. The Mann-Whitney U 
test was used to compare protein expression levels between groups. 
The χ2-test was used to assess associations between molecular mark-
ers. Survival distributions were estimated using the Kaplan-Meier 
method with the log-rank test. A Cox proportional hazards model was 
created to identify independent predictors of survival. In all cases, a 
P value of less than 0.05 was considered statistically significant.
Study approval. All mice were maintained and handled in accor-
dance with recommendations for the proper care and use of laboratory 
animals. The animal studies were conducted and performed under a 
protocol approved by the Korea University Institutional Animal Care and 
Use Committee (KUIACUC-2014-175). Approval for use of human mate-
rial in research was obtained from the Korea Gynecologic Cancer Bank 
through the Bio and Medical Technology Development Program of the 
Ministry of Education, Science, and Technology (Seoul, South Korea).
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sciences) mixed with Opti-MEM (Thermo Fisher Scientific). Cells were 
suspended in serum-free medium, and 5 × 104 cells were added to the 
Transwell insert. Cells were incubated for 24 hours at 37°C in a CO2 incu-
bator. Afterwards, cells that had migrated into the lower surface of the 
insert filter were washed twice with PBS, fixed with ethanol, and stained 
with 0.1% crystal violet dye. Cells were counted under a light microscope.
γ-H2AX analysis. Cells (1 × 105) were harvested by trypsinization, 
washed, and resuspended in PBS. To detect cellular γH2AX levels, 
cells were stained with anti–γ-H2AX followed by Alexa Fluor 488 goat 
anti–rabbit IgG (A11034, Invitrogen, Thermo Fisher Scientific). The 
frequency of γH2AX-positive cells was analyzed using a FACSVerse 
Flow Cytometer (BD Biosciences).
Tumor treatment experiments. C57BL/6 and NOD/SCID mice were 
inoculated s.c. with 105 tumor cells. For adoptive transfer experiments, 
mice were administered 2 × 106 E7-specific CTLs or an isotonic saline 
control by tail-vein injection 7 days after tumor challenge. For antiox-
idant combination therapy, mice were administered NAC (100 mg/
kg) in conjunction with adoptive T cell transfer or cisplatin (2 mg/kg) 
treatment. Tumor dimensions (length and width) were measured with 
a caliper every 3 to 4 days, and the tumor volume was calculated as 
length (mm) × width2 (mm2) × 0.52.
2D protein electrophoresis and MALDI–time-of-flight mass spec-
trometry. TC-1 P0 and TC-1 P3 cells in lysis buffer (7 M urea, 2 M 
thiourea, 4.5% CHAPS, 100 mM DTE, 40 mM Tris, pH 8.8) were 
applied to immobilized pH 3–10 nonlinear gradient strips (Amer-
sham Biosciences). Isoelectric focusing on the first axis was per-
formed at 80,000 Vh. Protein was run down a second orthogonal 
axis on a 9% to 16% linear gradient polyacrylamide gel at 40 mA 
for 5 hours. Protein was fixed in 40% methanol and 5% phosphor-
ic acid for 1 hour, and the gel was stained with CBB G-250 for 12 
hours. The gel was destained with H2O and scanned in a GS710 
Densitometer (Bio-Rad). Twelve protein spots with differential 
intensities in P0 versus P3 cells were excised and digested with 
endoproteinase. For MALDI–time-of-flight mass spectrometry 
(MALDI-TOF MS), peptide fragments derived from protein spots 
were concentrated on a POROS R2/Oligo R3 Column (Applied 
Biosystems). The column was first washed sequentially with 70% 
acetonitrile, 100% acetonitrile, and 50 mM ammonium bicarbon-
ate. Samples were applied to the column and eluted with cyano- 
4-hydroxycinamic acid (MilliporeSigma). Samples were dissolved in 
70% acetonitrile and 2% formic acid and loaded onto an Opti-TOF 
384 Well MALDI Plate Insert (Applied Biosystems). MALDI-TOF MS 
was performed on a 4800 MALDI-TOF/TOF Analyzer (Applied Bio-
systems) equipped with a 355-nm Nd:YAG laser. The pressure in the 
TOF analyzer is approximately 7.6 × 10–7 Torr. The mass spectra were 
obtained in the reflectron mode with an accelerating voltage of 20 kV 
and summed over 500 laser pulses. Calibration was performed using 
the 4700 Calibration Mixture (Applied Biosystems).
Tissue microarrays. Tissue microarrays were constructed with 
a TMArrayer machine (Pathology Devices), reviewed by a patholo-
gist, and annotated on H&E-stained slides. Four 1.0-mm-diameter 
cylindrical tissue cores consisting of a matched tumor specimen and 
normal epithelial tissue were then taken from corresponding regions 
of the donor paraffin blocks and transplanted into recipient paraffin 
blocks. Paraffin blocks were provided by the Korea Gynecologic Can-
cer Bank through the Bio and Medical Technology Development Pro-
gram of the Ministry of Education, Science, and Technology of Korea.
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